Key result
Heterologous mRNA-based booster vaccines provide an effective and safe approach to protect individuals from COVID-19 caused by emerging variants of concern.
Why the study?
As SARS-CoV-2 variants of concern emerge, COVID-19 booster strategies must adapt, prompting an evaluation of the immunogenicity, effectiveness, and safety of heterologous mRNA-based vaccination regimens.
Do heterologous mRNA-based vaccination strategies provide effective and safe protection against COVID-19 and emerging variants of concern?
Do heterologous mRNA-based vaccination strategies provide effective and safe protection against COVID-19 and emerging variants of concern?
Heterologous mRNA-based booster vaccines are an effective and safe strategy to maintain protection against emerging SARS-CoV-2 variants.
Heterologous mRNA boosting may enhance neutralization against VoCs; leaves open whether it improves clinical outcomes versus homologous regimens in randomized trials.
Messenger RNA (mRNA)-based vaccine platforms used for the development of mRNA-1273 and BNT162b2 have provided a robust adaptable approach to offer protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, as variants of concern (VoCs), such as omicron and associated sub-variants, emerge, boosting strategies must also adapt to keep pace with the changing landscape. Heterologous vaccination regimens involving the administration of booster vaccines different than the primary vaccination series offer a practical, effective, and safe approach to continue to reduce the global burden of coronavirus disease 2019 (COVID-19). To understand the immunogenicity, effectiveness, and safety of heterologous mRNA-based vaccination strategies, relevant clinical and real-world observational studies were identified and summarized. Overall, heterologous boosting strategies with mRNA-based vaccines that are currently available and those in development will play an important global role in protecting individuals from COVID-19 caused by emerging VoCs.
No takes yet. Share an insight, caveat, or question.
Das et al. (2023) conducted a review in COVID-19. Heterologous mRNA-based booster vaccines was evaluated. Heterologous mRNA-based booster vaccines provide an effective and safe approach to protect individuals from COVID-19 caused by emerging variants of concern.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: